N. Tabibzadeh, Dongyu Wang, A. Karaboyas, Elke Schaeffner, Stefan H. Jacobson, Almudena Vega, Kosaku Nitta, B. Bieber, R. Pecoits-Filho, Pablo Antonio Ureña Torres
{"title":"血液透析第一年的利尿剂处方:国际实践模式及其与疗效的关系","authors":"N. Tabibzadeh, Dongyu Wang, A. Karaboyas, Elke Schaeffner, Stefan H. Jacobson, Almudena Vega, Kosaku Nitta, B. Bieber, R. Pecoits-Filho, Pablo Antonio Ureña Torres","doi":"10.1093/ckj/sfae141","DOIUrl":null,"url":null,"abstract":"\n \n \n The use of diuretics in patients on hemodialysis (HD) is thought to maintain diuresis. However, this assumption and the optimal dose are based on little scientific evidence, and associations with clinical outcomes are unclear.\n \n \n \n We reported international variation in diuretic use and loop diuretic dose across 27 759 HD patients with dialysis vintage < 1 year in the Dialysis Outcomes and Practice Patterns Study (DOPPS) phases 2–5 (2002–2015), a prospective cohort study. Doses of torsemide (4:1) and bumetanide (80:1) were converted to oral furosemide-equivalent dose. Adjusted Cox, logistic, and linear regressions were used to investigate the association of diuretic use and dose with outcomes.\n \n \n \n Diuretic utilization varied widely by country at vintage < 3 months, ranging from > 80% in Germany and Sweden to < 35% in the US, at a median dose ranging from 400-500 mg/day in Germany and Sweden to <100 mg/day in Japan and the US. Neither diuretic use nor higher doses were associated with a lower risk of all-cause mortality, or a higher risk of hospitalization for fracture, or elevated PTH levels, but the prescription of higher doses (>200 mg/day) was associated with a higher risk of all-cause hospitalization.\n \n \n \n Substantial international differences exist in diuretic prescription, with usage and doses much higher in some European countries than the US. The prescription and higher doses of loop diuretics was not associated with improved outcomes.\n","PeriodicalId":10435,"journal":{"name":"Clinical Kidney Journal","volume":null,"pages":null},"PeriodicalIF":3.9000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diuretic prescriptions in the first year of hemodialysis: International practice patterns and associations with outcomes\",\"authors\":\"N. Tabibzadeh, Dongyu Wang, A. Karaboyas, Elke Schaeffner, Stefan H. Jacobson, Almudena Vega, Kosaku Nitta, B. Bieber, R. Pecoits-Filho, Pablo Antonio Ureña Torres\",\"doi\":\"10.1093/ckj/sfae141\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n \\n The use of diuretics in patients on hemodialysis (HD) is thought to maintain diuresis. However, this assumption and the optimal dose are based on little scientific evidence, and associations with clinical outcomes are unclear.\\n \\n \\n \\n We reported international variation in diuretic use and loop diuretic dose across 27 759 HD patients with dialysis vintage < 1 year in the Dialysis Outcomes and Practice Patterns Study (DOPPS) phases 2–5 (2002–2015), a prospective cohort study. Doses of torsemide (4:1) and bumetanide (80:1) were converted to oral furosemide-equivalent dose. Adjusted Cox, logistic, and linear regressions were used to investigate the association of diuretic use and dose with outcomes.\\n \\n \\n \\n Diuretic utilization varied widely by country at vintage < 3 months, ranging from > 80% in Germany and Sweden to < 35% in the US, at a median dose ranging from 400-500 mg/day in Germany and Sweden to <100 mg/day in Japan and the US. Neither diuretic use nor higher doses were associated with a lower risk of all-cause mortality, or a higher risk of hospitalization for fracture, or elevated PTH levels, but the prescription of higher doses (>200 mg/day) was associated with a higher risk of all-cause hospitalization.\\n \\n \\n \\n Substantial international differences exist in diuretic prescription, with usage and doses much higher in some European countries than the US. The prescription and higher doses of loop diuretics was not associated with improved outcomes.\\n\",\"PeriodicalId\":10435,\"journal\":{\"name\":\"Clinical Kidney Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Kidney Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ckj/sfae141\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Kidney Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ckj/sfae141","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Diuretic prescriptions in the first year of hemodialysis: International practice patterns and associations with outcomes
The use of diuretics in patients on hemodialysis (HD) is thought to maintain diuresis. However, this assumption and the optimal dose are based on little scientific evidence, and associations with clinical outcomes are unclear.
We reported international variation in diuretic use and loop diuretic dose across 27 759 HD patients with dialysis vintage < 1 year in the Dialysis Outcomes and Practice Patterns Study (DOPPS) phases 2–5 (2002–2015), a prospective cohort study. Doses of torsemide (4:1) and bumetanide (80:1) were converted to oral furosemide-equivalent dose. Adjusted Cox, logistic, and linear regressions were used to investigate the association of diuretic use and dose with outcomes.
Diuretic utilization varied widely by country at vintage < 3 months, ranging from > 80% in Germany and Sweden to < 35% in the US, at a median dose ranging from 400-500 mg/day in Germany and Sweden to <100 mg/day in Japan and the US. Neither diuretic use nor higher doses were associated with a lower risk of all-cause mortality, or a higher risk of hospitalization for fracture, or elevated PTH levels, but the prescription of higher doses (>200 mg/day) was associated with a higher risk of all-cause hospitalization.
Substantial international differences exist in diuretic prescription, with usage and doses much higher in some European countries than the US. The prescription and higher doses of loop diuretics was not associated with improved outcomes.
期刊介绍:
About the Journal
Clinical Kidney Journal: Clinical and Translational Nephrology (ckj), an official journal of the ERA-EDTA (European Renal Association-European Dialysis and Transplant Association), is a fully open access, online only journal publishing bimonthly. The journal is an essential educational and training resource integrating clinical, translational and educational research into clinical practice. ckj aims to contribute to a translational research culture among nephrologists and kidney pathologists that helps close the gap between basic researchers and practicing clinicians and promote sorely needed innovation in the Nephrology field. All research articles in this journal have undergone peer review.